A. PFEIFER ET AL: "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients", THE JOURNAL OF NUCLEAR MEDICINE, vol. 56, no. 6, 7 May 2015 (2015-05-07), pages 847-854, XP055414823, US ISSN: 0161-5505, DOI: 10.2967/jnumed.115.156539 (B1)

A. PFEIFER ET AL: "Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study", THE JOURNAL OF NUCLEAR MEDICINE, vol. 53, no. 8, 10 July 2012 (2012-07-10), pages 1207-1215, XP055163911, ISSN: 0161-5505, DOI: 10.2967/jnumed.111.101469 (B1)

R. SRIRAJASKANTHAN ET AL: "The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy", THE JOURNAL OF NUCLEAR MEDICINE, vol. 51, no. 6, 19 May 2010 (2010-05-19), pages 875-882, XP055414643, US ISSN: 0161-5505, DOI: 10.2967/jnumed.109.066134 (B1)

Jason S. Lewis ET AL: "Comparative Dosimetry of Copper-64 and Yttrium- 90-Labeled Somatostatin Analogs in a Tumor-Bearing Rat Model", CANCER BIOTHERAPY& RADIOPHARMACEUTICALS Volume, 1 January 2000 (2000-01-01), pages 593-604, XP055164025, Retrieved from the Internet: URL:http://online.liebertpub.com/doi/pdfpl us/10.1089/cbr.2000.15.593 [retrieved on 2015-01-21] (B1)

HIROFUMI HANAOKA ET AL: "Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors", ANNALS OF NUCLEAR MEDICINE, vol. 23, no. 6, 6 June 2009 (2009-06-06), pages 559-567, XP055147723, ISSN: 0914-7187, DOI: 10.1007/s12149-009-0274-0 (B1)